Genelux (GNLX) Non Operating Income (2022 - 2026)
Genelux (GNLX) posted quarterly Non Operating Income of $243000.0 for Q1 2026, down 25.0% year-over-year from $324000.0 in Q1 2025, and up 47.27% quarter-over-quarter from $165000.0 in Q4 2025.
Genelux (GNLX) Non Operating Income (2022 - 2026) Analysis & Trends
Genelux's Non Operating Income history runs 5 years deep, the most recent figure standing at $243000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 25.0% year-over-year to $243000.0; the TTM figure through Mar 2026 stood at $988000.0 (down 47.61% YoY), while the FY2025 annual figure was $1.1 million, down 41.49% from the prior year.
- Non Operating Income for Q1 2026 stood at $243000.0, up from $165000.0 in the prior quarter.
- The five-year high for Non Operating Income was $772000.0 in Q4 2024, with the low at -$3.9 million in Q1 2023.
- The 5-year median for Non Operating Income is $243000.0 (2026), against an average of -$115266.7.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 1347.37% in 2024, then tumbled 78.63% in 2025.
- Genelux's Non Operating Income stood at -$401000.0 in 2022, then surged by 158.35% to $234000.0 in 2023, then jumped by 229.91% to $772000.0 in 2024, then sank by 78.63% to $165000.0 in 2025, then soared by 47.27% to $243000.0 in 2026.
- Business Quant data shows GNLX's Non Operating Income at $243000.0 in Q1 2026, $165000.0 in Q4 2025, and $244000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 243,000.00 |
| Dec 31, 2025 | 165,000.00 |
| Sep 30, 2025 | 244,000.00 |
| Jun 30, 2025 | 336,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Jun 30, 2024 | 316,000.00 |
| Mar 31, 2024 | 265,000.00 |
| Dec 31, 2023 | 234,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | -426,000.00 |
| Mar 31, 2023 | -3.90 Mn |
| Dec 31, 2022 | -401,000.00 |
| Sep 30, 2022 | -335,000.00 |